# OnCo record paper-epcore-nhl-1-epcoritamab-jco-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-epcore-nhl-1-epcoritamab-jco-2023" ;
schema:name "EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T"@en ;
schema:description "In EPCORE NHL-1, the off-the-shelf bispecific antibody epcoritamab, injected under the skin, produced responses in 63% of 157 patients with relapsed large B-cell lymphoma, including the 39% whose CAR-T had failed. Cytokine release syndrome occurred in half, mostly mild, and the drug won accelerated approval in 2023."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:citation , ;
schema:sameAs ;
schema:datePublished "2023"^^xsd:gYear ;
schema:author "Thieblemont C, Phillips T, Ghesquieres H, et al." ;
onco:related ;
onco:cancers , ;
onco:technologies , ;
onco:targets , ;
onco:drugs , , , ;
onco:companies , ;
onco:terms , , ;
onco:trials , , ;
onco:bottlenecks , ;
onco:journals .